Sai Life Sciences Ltd (SAILIFE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sai Life Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Earnings Call details for unaudited financial results for the second quarter and half year ended 30th September 2026.
Intimation · 06 Nov 2026, 11:00 am
Sai Life Sciences Schedules Q2FY27 Earnings Conference Call Sai Life Sciences will host an earnings conference call for analysts and investors on 6th Nov'26 at 11:00 AM IST to discuss its unaudited standalone and consolidated financial results for Q2 and H1 ended 30th Sep'26 (Q2FY27). Senior management, including Managing Director & CEO Krishna Kanumuri and Whole-Time Director & CFO Siva Chittor, will represent the company. The session will feature a management discussion on earnings performance followed by an interactive Q&A session. Primary dial-in numbers are +91 22 6280 1107 and +91 22 7115 8008.
Allotment of 54,500 Equity Shares having Face Value of Rs. 1/- each, as per Companies ESOP Plan
Others (Uncategorized) · 13 Oct 2026, 12:51 am
Sai Life Sciences Allots 54,500 Equity Shares Under ESOP 2008 Sai Life Sciences approved the allotment of 54,500 fully paid-up equity shares (face value ₹1 each) on 12th Oct'26 following the exercise of options under ESOP 2008 at an exercise price of ₹188.90 per share (including a premium of ₹187.90 per share). Consequently, the company's issued, subscribed, and paid-up equity share capital expanded from ₹21,24,18,217 to ₹21,24,72,716, divided into 21,24,72,716 equity shares. The newly allotted shares rank pari passu with existing equity shares.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Sai Life Sciences Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 05 Nov 2026, 5:30 am
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited financial results ....
Intimation · 05 Nov 2026, 5:30 am
Sai Life Sciences Schedules Board Meeting for Q2 and H1 Financial Results Sai Life Sciences Limited has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26, alongside other corporate matters. In accordance with insider trading regulations, the trading window for dealing in company securities was closed on 1st Oct'26 and will remain closed until 7th Nov'26 (48 hours post-result announcement) for all designated persons and their immediate relatives.
Allotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company''s ESOP Plan
Others (Uncategorized) · 18 Sept 2026, 11:40 pm
Sai Life Sciences Allots 24,000 Equity Shares Under ESOP 2008 Sai Life Sciences approved the allotment of 24,000 fully paid-up equity shares of face value ₹1 each on 18th Sep'26 via circular resolution, following the exercise of stock options under its ESOP 2008 scheme. The shares were issued at an exercise price of ₹188.90 per share, including a premium of ₹187.90 per share. Consequently, the company's paid-up equity share capital increased from ₹21,23,94,217 (21,23,94,217 shares) to ₹21,24,18,216 (21,24,18,216 shares). The newly allotted shares rank pari-passu with existing equity shares.
Voting Results and Scrutinizer''s Report of 27th Annual General Meeting (AGM) of the Company
Annual General Meeting · 17 Sept 2026, 10:09 pm
Proceedings of 27th Annual General Meeting (AGM) of the Company
Annual General Meeting · 17 Sept 2026, 6:28 pm
Investors Conference - 18th September 2026
Intimation · 04 Sept 2026, 10:16 pm
Sai Life Sciences to Attend Jefferies 5th India Forum Sai Life Sciences officials will participate in the Jefferies 5th India Forum on 18th Sep'26 in Gurgaon from 9:00 AM to 6:00 PM IST. The event involves in-person group and one-on-one meetings with analysts and institutional investors. Discussions will focus strictly on publicly available information without sharing any unpublished price-sensitive information.
Investors Conference - 14th September 2026
Intimation · 04 Sept 2026, 10:10 pm
Sai Life Sciences to Attend Morgan Stanley Healthcare Conference Sai Life Sciences Limited officials will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on 14th Sep'26 in New York. The in-person meetings will be conducted in both group and one-on-one formats between 09:00 AM and 06:00 PM EST. Discussions will strictly rely on publicly available information, with no unpublished price-sensitive information being shared.
Allotment of 80,600 Equity shares having Face Value ?1/- each as per Company''s ESOP Plans
Others (Uncategorized) · 01 Sept 2026, 8:43 pm
Sai Life Sciences Allots Equity Shares Under Employee Stock Plans Sai Life Sciences approved the allotment of 80,600 new equity shares on 01 Sep'26 following the exercise of options under its ESOP 2008 and MESOP 2018 schemes. This includes 14,600 shares at an exercise price of ₹188.90 and 66,000 shares at ₹23.30. Consequently, the company's issued, subscribed, and paid-up equity share capital increased from ₹21,23,13,617 to ₹21,23,94,216. The new shares have a face value of ₹1 each and will rank pari-passu with existing equity shares.
Please refer the attachment
Others (Uncategorized) · 26 Aug 2026, 12:26 am
Sai Life Sciences Announces 27th AGM and FY26 Annual Report Access Sai Life Sciences will hold its 27th Annual General Meeting (AGM) via video conference on 17 Sep'26 at 10:30 AM IST. The company has dispatched a letter containing the web link to its Integrated Annual Report for FY 2025-26 to shareholders who have not registered an email address as of the 14 Aug'26 cut-off date. This action complies with SEBI's Listing Obligations and Disclosure Requirements regulations. The company encourages shareholders to register their email addresses for future electronic communications.
Business Responsibility and Sustainability Report (BRSR) and ESG Databook of Sai Life Sciences Limited for the FY 2025-26
Others (Uncategorized) · 26 Aug 2026, 12:22 am
Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-26
Others (Uncategorized) · 26 Aug 2026, 12:15 am
Notice of 27th Annual General Meeting (AGM) of the Company
Annual General Meeting · 26 Aug 2026, 12:04 am
Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.
Annual General Meeting · 24 Aug 2026, 6:28 pm
Transcript of Earnings Conference Call organised on 07 August 2026
Transcript · 12 Aug 2026, 7:09 pm
Recording of Earnings Call for the Unaudited Financial Results of the Company for the quarter ended on 30 June 2026.
Audio / Video · 08 Aug 2026, 12:16 am
Sai Life Sciences Q1 FY27 Earnings Call Recording Published Sai Life Sciences has published the recording of its earnings call, held on 07 Aug'26, discussing the un-audited financial results for the quarter ended 30 Jun'26. The company provided a link to the audio recording on its website for investor access, fulfilling regulatory disclosure requirements. No financial details were included in this specific notification.
Investor Presentation for the quarter ended on 30 June 2026
Investor Presentation · 07 Aug 2026, 7:18 pm
Sai Life Sciences Q1FY27: Solid Growth Driven by CRO Momentum Sai Life Sciences reported strong Q1FY27 results with revenue of ₹554 Cr, up 12% YoY, and PAT of ₹73 Cr, up 22% YoY. The CRO business was a key driver, growing 24% YoY, while the overall revenue mix was 60% CDMO and 40% CRO. EBITDA increased 18% YoY to ₹148 Cr with a margin of 27%. The CMC pipeline remains robust with 33 commercial and 14 late-phase molecules. The company reiterated its long-term revenue growth guidance of 15-20% and an EBITDA range of 28-30%.
Allotment of 18,700 equity shares under Employee Stock Option Plan
Others (Uncategorized) · 07 Aug 2026, 5:21 am
Sai Life Sciences Allots 18,700 Equity Shares Under ESOP 2008 On 06 Aug'26, Sai Life Sciences' Board approved the allotment of 18,700 fully paid-up equity shares of Rs. 1 each under its ESOP 2008 scheme. The shares were issued upon exercise of options at a price of Rs. 188.90 per share, realizing total proceeds of INR 35.32 lakh. Following this allotment, the company's total issued share capital increased to 21,23,13,616 shares. The newly issued shares are listed on both BSE and NSE. This action is a minor, routine equity dilution.
Press Release for the Unaudited financial results for the quarter ended 30 June 2026
Press Release · 07 Aug 2026, 4:46 am
Sai Life Sciences Reports Strong Q1 FY27 with 22% YoY Net Profit Growth Sai Life Sciences reported a strong start to FY27, with Q1 revenue from operations rising 12% YoY to ₹554 Cr. EBITDA grew 18% YoY to ₹148 Cr, with EBITDA margin expanding to 27% from 25% in Q1FY26. Profit After Tax (PAT) saw robust growth of 22% YoY, reaching ₹73 Cr. The Contract Research Organization (CRO) business was a key driver, growing 24% YoY. The company's CMC pipeline remains strong with 33 active commercial molecules. An earnings call is scheduled for 07 Aug'26.
Unaudited Financial results (Standalone and Consolidate) for the Quarter ended on 30 June 2026
Financial Result · 07 Aug 2026, 4:01 am
Sai Life Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 5,543 (+11.7% YoY | -7.9% QoQ) ■ EBITDA: 1,480 (+22.4% YoY | -16.2% QoQ) ■ EBITDA Margin (%): 26.7 (+234 bps YoY | -262 bps QoQ) ■ PAT: 733 (+21.2% YoY | -29.7% QoQ) ■ EPS (INR): 3.42 (+20.8% YoY | -29.8% QoQ)
Board Meeting Outcome for Approval of Unaudited Financial Results (Standalone and Consolidated) For the Quarter Ended On 30 June 2026
Outcome · 07 Aug 2026, 3:56 am
Sai Life Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 5,543 (+11.7% YoY | -7.9% QoQ) ■ EBITDA: 1,480 (+22.4% YoY | -16.2% QoQ) ■ EBITDA Margin (%): 26.7 (+234 bps YoY | -262 bps QoQ) ■ PAT: 733 (+21.2% YoY | -29.7% QoQ) ■ EPS (INR): 3.42 (+20.8% YoY | -29.8% QoQ)
Analyst/Investor Meet on 13 August 2026 and 14 August 2026 at Singapore
Intimation · 05 Aug 2026, 2:35 am
Sai Life Sciences to Meet Investors at Avendus Spark Conference Sai Life Sciences (SAILIFE) has scheduled one-on-one and group meetings with analysts and investors on 13-Aug'26 and 14-Aug'26. The meetings will take place in Singapore as part of the Avendus Spark INDX-Asia Edition 2026 conference. The company stated that no new presentation will be made and it does not intend to discuss any unpublished price-sensitive information. The schedule is subject to change based on exigencies from any of the involved parties.
Earnings Conference call Invite to discuss Un-audited Financial Results of the Company for the Quarter ended 30 June 2026.
Intimation · 07 Aug 2026, 4:00 pm
Sai Life Sciences Schedules Q1FY27 Earnings Call for 07 Aug'26 Sai Life Sciences will host an earnings conference call on 07 Aug'26 at 4:00 PM IST to discuss its unaudited financial results for the quarter ended 30 Jun'26. Senior management, including MD & CEO Krishna Kanumuri and Director & CFO Siva Chittor, will lead the call. This event is a key opportunity for investors to gain insights into the company's Q1FY27 performance and outlook. The call will include a management discussion followed by an interactive Q&A session for analysts.